Compare CLVT & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLVT | IVA |
|---|---|---|
| Founded | 2016 | 2011 |
| Country | United Kingdom | France |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | 2020 | 2020 |
| Metric | CLVT | IVA |
|---|---|---|
| Price | $2.14 | $4.65 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 10 |
| Target Price | $3.22 | ★ $16.20 |
| AVG Volume (30 Days) | ★ 5.1M | 673.2K |
| Earning Date | 04-29-2026 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 68.75 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $974,345,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.12 | $751.20 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 0.61 | N/A |
| 52 Week Low | $1.66 | $3.35 |
| 52 Week High | $4.54 | $7.98 |
| Indicator | CLVT | IVA |
|---|---|---|
| Relative Strength Index (RSI) | 56.44 | 52.98 |
| Support Level | $2.09 | $4.48 |
| Resistance Level | $2.69 | $4.70 |
| Average True Range (ATR) | 0.12 | 0.16 |
| MACD | 0.04 | -0.02 |
| Stochastic Oscillator | 97.22 | 39.80 |
Clarivate is a data, information, and software workflow solutions company serving customers primarily in academia, government, law, life sciences, and healthcare. The company was formerly part of Thomson Reuters before being sold to private equity as an independent company in 2016. In 2019, Clarivate went public on the New York Stock Exchange. Around half of the company's revenue is generated in the Americas, while Europe, Middle East, and Africa account for around a quarter.
Inventiva SA is a France-based clinical-stage biopharmaceutical company focused on the development of oral small-molecule therapies for the treatment of MASH. The wholly-owned research and development facility and a team with expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging the expertise, the company is also advancing lanifibranor for the treatment of MASH and has a pipeline of earlier-stage therapeutic programs in oncology. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France.